

Supplementary Table 1. Comparison of Baseline Characteristics According to Annual eGFR Decline

Variables	Total (N = 57)	Non-rapid GFR loss (n = 41)	Rapid GFR loss (n = 16)	P value
Median (IQR: 25th-75th) or n (%)				
Age at diagnosis, y	40 (35-51)	40 (34.5-51)	45 (36-56)	.379
Gender (female)	26 (45.6)	16 (39)	10 (62.5)	.110
Hypertension	29 (50.9)	20 (48.8)	9 (56.3)	.612
Diabetes mellitus	7 (12.3)	2 (4.9)	5 (31.3)	.015
Laboratory findings at baseline median (IQR: 25th-75th)				
Serum creatinine, mg/dL	1 (0.75-1.41)	1.14 (0.87-1.45)	0.77 (0.66-1.27)	.025
Proteinuria, mg/d	1091 (566.5-2021)	1055 (574.5-2021)	1564.5 (560.75-2982)	.315
Albuminuria, mg/d	725 (350-1250)	685 (275.5-1245)	1002.5 (353.75-2230.25)	.295
eGFR (mL/min/1.73m ²)	77 (61-108)	76 (57-95.5)	99 (69.75-118.25)	.088
Neutrophil count, ×10 ⁹ /L	4.4 (3.82-4.97)	4.3 (3.8-4.83)	4.84 (4.01-5.21)	.145
Lymphocyte count, ×10 ⁹ /L	2.1 (1.9-2.2)	2.1 (1.9-2.17)	2.15 (2.10-2.40)	.032
Platelet count, ×10 ⁹ /L	198 (167.5-255)	210 (166-255)	196 (172-267)	.528
Hemoglobin, g/dL	12.4 (11.3-13.45)	11.90 (11.3-13.5)	12.4 (11.82-13.4)	.630
Histopathological findings n (%)				
Crescents	0 (0-3.3)	0 (0-0)	0 (0-5)	.101
Global sclerosis	8 (3.92-26.25)	7.10 (2.99-19.85)	15.20 (5.94-36)	.091
Segmental sclerosis	6.6 (3.08-12.90)	6.6 (3.16-13.45)	7.1 (2.99-19.85)	.796
Treatment n (%)				
Immunosuppressive therapy	24 (42.1)	21 (51.2)	3 (18.8)	.037
RRT	1 (1.8)	0	1 (6.3)	.281

Abbreviations: eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; IQR, interquartile range; RRT, renal replacement therapy; mg/dL, milligrams per deciliter; mg/day, milligrams per day.